Acetazolamide
Small molecule targets CA1, CA12, CA2, CA4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DIAMOX | — | 1953-07-27 | fda.gov ↗ |
Trials 87 · started per year
Also used as a comparator or background therapy in 71 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07517068 Comparator | Sep 2025 → Jun 2026 overdue | acute mountain sickness | University of California, Riverside | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03525561 Comparator | Oct 2018 → May 2019 | cognitive disorder | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03963336 Comparator | Jul 2017 → Jul 2018 | pseudotumor cerebri | Fayoum University | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04470843 Comparator | Aug 2018 → Mar 2021 | prostate cancer | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1 | NCT03154645 Comparator | Aug → Oct 2017 | acute mountain sickness | Grant S Lipman | Completed | No outcome recorded |
| Phase 1 | NCT00780325 Comparator | Oct 2008 → Jul 2013 | — | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05293600 Comparator | Jul 2023 → Oct 2026 expected | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05589792 Comparator | Jan 2023 → Dec 2025 | obstructive sleep apnea syndrome | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04887792 Comparator | Feb 2022 → Dec 2027 expected | schizoaffective disorder, schizophrenia | Vishwajit Nimgaonkar, MD PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01187108 Comparator | Jun → Sep 2013 | chronic mountain sickness, polycythemia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07372040 Comparator | Feb 2026 → Feb 2027 expected | heart failure | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06776432 Comparator | Apr 2025 → Dec 2026 expected | sleep apnea syndrome | Shionogi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05290948 Comparator | Mar → Jul 2022 | macular retinal edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04975269 Comparator | Feb 2022 → Nov 2024 | normal pressure hydrocephalus | Uppsala University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03763227 Comparator | Jul 2015 → Aug 2019 | inherited retinal dystrophy | Sultan Qaboos University | Completed | No outcome recorded |
| Phase 2 | NCT02760901 Comparator | Nov 2013 → Oct 2015 | cisplatin toxicity | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT00634491 Comparator | Sep 2007 → Feb 2008 | acute tubulointerstitial nephritis | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06783166 Comparator | Aug 2024 → Jul 2025 overdue | heart failure | Mansoura University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06146101 Comparator | May 2024 → Dec 2026 expected | obstructive sleep apnea syndrome | Incannex Healthcare Ltd | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02945527 Comparator | Dec 2015 → Dec 2018 | cysticercosis | Universidad Peruana Cayetano Heredia | Terminated | No outcome recorded |
| Phase 2/3 | NCT01003639 Comparator | Jan 2010 → Jun 2013 | pseudotumor cerebri | St. Luke's-Roosevelt Hospital Center | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06535529 Comparator | Aug 2024 → Aug 2025 overdue | heart failure | Helwan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05707442 Comparator | Feb 2023 → Jan 2027 expected | spontaneous intracranial hypotension | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04913389 Comparator | Jun 2021 → Aug 2022 | altitude sickness, chronic obstructive pulmonary disease | University of Zurich | Unknown | No outcome recorded |
| Phase 3 | NCT03501966 Comparator | Feb → Aug 2019 | pseudotumor cerebri | Jaeb Center for Health Research | Terminated | No outcome recorded |
| Phase 3 | NCT02604173 Comparator | Aug → Sep 2016 | acute mountain sickness | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02163330 Comparator | Jun 2014 → Jan 2017 | — | Rabin Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00637468 Comparator | Sep 2002 → ? | central retinal artery occlusion, stroke disorder | University Hospital Freiburg | Terminated | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT07101250 Comparator | Oct 2025 → Aug 2026 overdue | myofascial pain syndrome | Prisma Health-Upstate | Recruiting | No outcome recorded |
| Phase 4 | NCT06166654 Comparator | Sep 2024 → Sep 2027 expected | heart failure | Johannes Grand | Recruiting | No outcome recorded |
| Phase 4 | NCT06499727 Comparator | Jul 2024 → Aug 2025 | acute mountain sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT06498531 Comparator | Jul 2024 → Aug 2025 | sleep apnea syndrome | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT06498505 Comparator | Jul 2024 → Aug 2025 | altitude sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT05986773 Comparator | Oct 2023 → Dec 2024 | heart failure | Stadtspital Zürich | Terminated | No outcome recorded |
| Phase 4 | NCT05575180 Comparator | Aug 2023 → Feb 2024 | altitude sickness | University of Waterloo | Completed | No outcome recorded |
| Phase 4 | NCT05904808 Comparator | Apr → Aug 2023 | congestive heart failure | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT04118387 Comparator | Jan 2021 → Dec 2026 expected | central sleep apnea syndrome | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT04227093 Comparator | Jan 2020 → Apr 2023 | obstructive sleep apnea syndrome | University Hospital, Antwerp | Unknown | No outcome recorded |
| Phase 4 | NCT03540914 Comparator | Jun 2018 → Dec 2024 | altitude sickness | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT03539367 Comparator | Jun 2018 → Dec 2022 | altitude sickness | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT03537924 Comparator | Jun 2018 → Dec 2022 | altitude sickness | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT03540901 Comparator | May → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03536520 Comparator | May → Aug 2018 | altitude sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03536455 Comparator | May → Aug 2018 | altitude sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03536429 Comparator | May → Aug 2018 | altitude sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03561675 Comparator | May 2018 → Aug 2019 | acute mountain sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03536507 Comparator | May → Aug 2018 | altitude sickness | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03165890 Comparator | May → Jul 2017 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03177837 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03177850 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03173508 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03167034 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03177811 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03156231 Comparator | May 2017 → Aug 2018 | chronic obstructive pulmonary disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT01889498 Comparator | Jul 2014 → Jun 2016 | thoracic aortic aneurysm | Liverpool Heart and Chest Hospital NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 4 | NCT01627639 Comparator | Oct 2011 → Jul 2014 | chronic obstructive pulmonary disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01418157 Comparator | Aug → Oct 2011 | acute mountain sickness | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT01228149 Comparator | Aug 2010 → Apr 2014 | glaucoma | Katrin Lorenz | Completed | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00424970 Comparator | Jan → Nov 2007 | polycythemia due to hypoxia | Association pour la Recherche en Physiologie de l'Environnement | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07707544 Comparator | Jun → Dec 2026 expected | pseudotumor cerebri | Sohag University | Active not recruiting | No outcome recorded |
| — | NCT06945848 Comparator | Jan 2026 → Jan 2029 expected | pseudotumor cerebri | University Hospital, Montpellier | Recruiting | No outcome recorded |
| — | NCT06919744 Comparator | Sep 2025 → Oct 2028 expected | pseudotumor cerebri | University Hospital, Montpellier | Recruiting | No outcome recorded |
| — | NCT06362668 Comparator | May → Oct 2024 | heart failure | Reprieve Cardiovascular, Inc | Completed | No outcome recorded |
| — | NCT02972411 Comparator | Oct 2016 → May 2017 | altitude sickness | Hospital del Trabajador de Santiago | Unknown | No outcome recorded |
| — | NCT01750723 Comparator | Dec 2012 → Apr 2013 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT01519544 Comparator | Mar → Jul 2012 | sleep disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT02140450 Comparator | Feb 2012 → Jan 2014 | — | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01060969 Background | Jan 2006 → Aug 2010 | brain edema, pulmonary edema | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT01923454 Background | Dec 2005 → Jun 2007 | acute closed-angle glaucoma | Siriraj Hospital | Completed | No outcome recorded |
| — | NCT00120731 Background | Jul 2005 → May 2007 | nephrolithiasis | Children's Mercy Hospital Kansas City | Withdrawn | No outcome recorded |
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 162 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetazolamide | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗157“RESEARCH QUESTION: Is 2 weeks of 500 mg acetazolamide plus 100 mg atomoxetine daily effective for OHS severity (reduction in mean nocturnal CO2 as the primary outcome)?” PMID 41015199 ↗ Sep 2025 “On the other hand injection of Diamox (Acetazolamide) apparently causes increase of the cerebral blod flow with out dilation of the arteries.” NCT00363571 ↗ “Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)” NCT01535768 ↗ “Acetazolamide will be introduced at the time of papilledema discovery.” NCT06919744 ↗ “Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy.” NCT01228149 ↗ “oral acetazolamide 500mg/day or topical brinzolamide twice daily” NCT03763227 ↗ “3. acetazolamide at a dose based on serum creatinine value” NCT04062760 ↗ |
| Known as | Acetamox | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Acetazolamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Acetazolamide (Diamox 250 mg) | “Acetazolamide (Diamox 250 mg)” NCT01923454 ↗ |
| Known as | acetazolamide = Zoladin | “acetazolamide = Zoladin” NCT01131377 ↗ |
| Known as | ACETAZOLAMIDE SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Acetazolamide sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Acetazolamide, oral capsule | “Acetazolamide, oral capsule” NCT04915365 ↗ |
| Known as | Acetazolamidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | ACTZ | “Acetazolamide (ACTZ) decreases serum bicarbonate concentration and stimulates respiratory drive.” PMID 28286047 ↗ Mar 2017 |
| Known as | Acz | “Prophylaxis of AMS is primarily based on the administration of 250 mg/day of acetazolamide (ACZ), a carbonic anhydrase inhibitor with a mild diuretic effect.” NCT07118462 ↗1“A preliminary study demonstrated the efficiency of acetazolamide (Acz) (250 mg/d for 3 wk) in reducing serum erythropoietin and hematocrit.” PMID 18388356 ↗ Apr 2008 |
| Known as | Atenezo | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | AZT | “The carbonic anhydrase inhibitor acetazolamide (AZT) modulates blood pressure at high altitude and reduces sleep-disordered breathing in patients with obstructive sleep apnea (OSA).” PMID 29510792 ↗ Mar 2018 |
| Known as | Defiltran | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Diamox | “To evaluate the additive value of tadalafil given together with Diamox (acetazolamide) in preventing acute mountain sickness in travelers to high altitude areas.” NCT01060969 ↗5“Acetazolamide (Diamox) has been shown to reduce the production of CSF in clinical cases of raised intracranial pressure” NCT02163330 ↗ “Acetazolamide (Diamox®) is a diuretic that acts at a different location in the kidney compared to the loop diuretics.” NCT03505788 ↗ “Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy.” NCT01228149 ↗ “Diamox” NCT03963336 ↗ |
| Known as | Diamox (acetazolamide) | “Diamox (acetazolamide)” NCT01973335 ↗ |
| Known as | Diamox (brand name for acetazolamide) | “Diamox (brand name for acetazolamide)” NCT05411991 ↗ |
| Known as | Diamox sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Didoc | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Diuriwas | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Donmox | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Edemox | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Eytazox | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Glaupax | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | L 579486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Nephramide | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | NSC-145177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Phonurit | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Sodium acetazolamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Known as | Vetamox | ChEMBL registry synonym — accepted as the source's own label CHEMBL20 ↗ |
| Action | Inhibit | “Carbonic anhydrase XII inhibitor” CHEMBL20 ↗4“Carbonic anhydrase IV inhibitor” CHEMBL20 ↗ “Carbonic anhydrase II inhibitor” CHEMBL20 ↗ “Carbonic anhydrase I inhibitor” CHEMBL20 ↗ “a carbonic anhydrase inhibitor” NCT00000115 ↗ |
| Modality | Small molecule | — CHEMBL20 ↗ |
| Route | Oral | “oral acetazolamide sodium 500 mg” NCT00000115 ↗ |
| Target | CA1 | “Carbonic anhydrase I inhibitor” CHEMBL20 ↗ |
| Target | CA12 | “Carbonic anhydrase XII inhibitor” CHEMBL20 ↗ |
| Target | CA2 | “Carbonic anhydrase II inhibitor” CHEMBL20 ↗ |
| Target | CA4 | “Carbonic anhydrase IV inhibitor” CHEMBL20 ↗ |